← Back to Search

mTOR inhibitor

Sirolimus for Coronavirus (SCOPE Trial)

Phase 2
Waitlist Available
Led By Nishant Gupta, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

SCOPE Trial Summary

This trial is testing whether the drug sirolimus can help improve outcomes for people hospitalized with COVID-19. 30 people will be randomly assigned to either receive sirolimus or a placebo, and will be monitored for changes in their condition.

Eligible Conditions
  • Coronavirus
  • COVID-19

SCOPE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Patients Who Are Alive and Free From Advanced Respiratory Support Measures at Day 28.
Secondary outcome measures
Drug Safety Profile
Duration of Hospital Stay
Number of Patients Who Require Initiation of Off-label Therapies
+1 more

SCOPE Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: SirolimusActive Control1 Intervention
Sirolimus 6mg on day 1 followed by 2mg daily for the next 13 days or until hospital discharge, whatever happens sooner.
Group II: PlaceboPlacebo Group1 Intervention
Matching placebo

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
428 Previous Clinical Trials
634,362 Total Patients Enrolled
Nishant Gupta, MD5.02 ReviewsPrincipal Investigator - University of Cincinnati
University of Cincinnati
2 Previous Clinical Trials
129 Total Patients Enrolled
5Patient Review
This professional was terrific. They had excellent knowledge and provided terrific explanations.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
Nishant Gupta, MD, MS 2020. "Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04341675.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top